<DOC>
	<DOCNO>NCT02818725</DOCNO>
	<brief_summary>OBJECTIVES OF THE TRIAL Primary objective Evaluation efficacy term progression-free survival 9 month combination intensified methotrexate , vinblastine , doxorubicin cisplatin without panitumumab first-line treatment advance urothelial carcinoma patient without Harvey Kirsten rat sarcoma viral oncogene homolog mutation . Secondary objective - To assess toxicity - To assess response rate - To assess overall survival - To assess time progression - To study correlation response rate , time progression , overall survival biological parameter</brief_summary>
	<brief_title>I-MVAC +/- Panitumumab First-line Treatment Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Primary tumour bladder upper urinary tract 2 . Histologically confirm infiltrate urothelial carcinoma ( epidermoid and/or glandular form accept ) 3 . Patients without Harvey Kirstenrat sarcoma viral oncogene homolog mutation 4 . Advanced disease define locally advanced stage ( T4 and/or N+ ) ineligible surgical resection , metastatic stage ( M1 ) 5 . Patients least 1 evaluable lesion per RECIST criterion ( version 1.1 ) 6 . 18 ≤ age ≤ 75 year 7 . General condition 0 1 per WHO scale 8 . Absence previous chemotherapy advance disease ( chemotherapy gemcitabine platinum salt deliver adjuvant accept end year ago ) 9 . Haematological function : Haemoglobin &gt; 11 g/dl , neutrophils ≥ 1500/mm3 , platelet ≥ 100,000/mm3 10 . Liver function : Grade* 0 Aspartate aminotransferase Alanine aminotransferase ( &lt; grade* 3 liver metastasis ) , grade* 0 alkaline phosphatase , normal bilirubin 11 . Renal function : calculate ( measure ) creatinine clearance &gt; 60 ml/min 12 . Patients cover social security scheme 13 . Patient read information sheet sign informed consent form . 1 . Pure adenocarcinoma pure epidermoid carcinoma mixed pure smallcell neuroendocrine carcinoma 2 . Previous treatment one follow molecule : methotrexate , vinblastine , doxorubicin Epidermal Growth Factor inhibitor 3 . History interstitial pneumonitis pulmonary fibrosis 4 . History cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , uncontrolled serious cardiac arrhythmia ) year prior randomisation ( ≤ 1 year ) 5 . Ventricular ejection fraction &lt; 50 % 6 . Blood calcium and/or magnesium ≥ grade* 1 7 . History cancer 5 year prior entry trial basal cell skin cancer situ epithelioma cervix , 8 . Treatment radiotherapy analgesic purpose ( unless treatment discontinue least 15 day prior inclusion trial ) 9 . Potential allergy panitumumab 10 . Male female patient agree use effective method contraception throughout duration treatment 6 month treatment discontinuation 11 . Pregnant woman , female subject liable become pregnant currently breastfeed , 12 . Patient already include another therapeutic trial investigational medicinal product , 13 . Persons deprive freedom judicial protection ( include guardianship ) , 14 . Unable receive medical followup trial owe geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>